231 results
Search Results
2. Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?
3. Strategien zur Vermeidung von Antibiotikaresistenzen
4. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
5. Pharmacokinetics of levodopa
6. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects
7. Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects
8. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
9. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
10. Entry-into-humans study with a new direct renin inhibitor
11. Pharmakotherapie im Alter aus internistisch-pneumologischer Sicht
12. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients
13. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
14. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
15. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts
16. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
17. Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes
18. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis
19. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
20. Antimikrobielle Therapie bei Patienten nach Verbrennungstrauma
21. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
22. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation
23. Characterisation of the iterative integral parameter identification method
24. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
25. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
26. Macitentan: entry-into-humans study with a new endothelin receptor antagonist
27. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats
28. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics
29. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
30. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
31. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
32. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
33. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
34. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
35. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
36. Umfrage zur Arzneimitteldosierung bei Niereninsuffizienz unter nephrologisch tätigen Ärzten
37. Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability
38. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
39. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
40. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker
41. Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT®) following oral administration in African malaria patients
42. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
43. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
44. Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women
45. A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression
46. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
47. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers
48. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans
49. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
50. Physiologische Besonderheiten des kindlichen Organismus: Relevanz für die Arzneimitteltherapie
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.